Embedded Files
What is INGR1D2 about?
What is INGR1D2 about?
INGR1D2 - INvestigating Genetic Risk for type 1 Diabetes (2) - is an important study that aims to identify children with genetic markers that show that they have an increased risk of developing type 1 diabetes. All maternity units in the North East North Cumbria, and several maternity units in the East of England (including Cambridge), are offering parents the chance to involve their babies in this large study. To date, over 40,000 babies in the UK have joined this study which is looking at how we might prevent type 1 diabetes in the future. Type 1 diabetes is a condition that cannot be cured and that needs life long treatment.
Click here to find out if your maternity unit is taking part in INGR1D2.
The INGR1D2 study is part of a programme of research led by the Global Platform for the Prevention of Auto Immune Disease (GPPAD). This platform supports expert researchers to work together with the aim of eradicating Type 1 Diabetes completely.
Click the video below to find out more about INGR1D2 and what it involves.
Taking part in the INGR1D2 study:
is voluntary. You can ask questions and take time to decide whether the study is right for you and your family
uses blood that already collected from your baby during the heel prick test taken at 5 days old. This means that no extra tests or visits are needed for babies taking part in INGR1D2. The heel prick test is routinely offered to all babies by the NHS.
estimates your baby's risk of developing Type 1 Diabetes during childhood by looking at their genes. It cannot predict with certainty whether your baby will or will not develop Type 1 Diabetes during their lifetime but it can tell you if there is a higher chance that they will develop the condition
offers the chance for babies who have a higher chance of developing Type 1 Diabetes to take in further, optional, research designed to prevent the condition from developing (called the the AVANT1A study )
If you are considering taking part in INGR1D2 then these pages are designed to help you to think about what is right for you and your baby.
What do parents say about taking part in the INGR1D2 study?
What do parents say about taking part in the INGR1D2 study?
Here you can hear from Emma and Brandon who took part in the INGR1D2 study. The results of the INGR1D2 study showed that their baby daughter, Robin, had a higher chance of developing Type 1 Diabetes during her childhood. Emma and Brandon decided to enrol Robin in the AVAnT1A study. AVAnT1A is looking at a treatment that might prevent babies at higher risk from developing Type 1 Diabetes. Children taking part in AVAnT1A have extra monitoring and visits with specialists which means that, if Robin does start to develop Type 1 Diabetes, it will be picked up as early as possible. To find out more about Emma, Brandon, and Robin's experiences of taking part in INGR1D2 and AVAnT1A click here.
What would you like to do next?
What would you like to do next?
Page updated
Report abuse